Critical intracellular signals in normal and malignant cells are transmitted by the adaptor protein Grb2 by means of its Src homology 2 (SH2) domain, which binds to phosphotyrosyl (pTyr) residues generated by the activation of tyrosine kinases. To understand this important control point and to design inhibitors, previous investigations have focused on the molecular mechanisms by which the Grb2 SH2 domain selectively binds pTyr containing peptides. In the current study, we demonstrate that the Grb2 SH2 domain can also bind in a pTyr independent manner. Using phage display, an 11-amino acid cyclic peptide, G1, has been identified that binds to the Grb2 SH2 domain but not the src SH2 domain. Synthetic G1 peptide blocks Grb2 SH2 domain association (IC 50 10 -25 M) with a 9-amino acid pTyrcontaining peptide derived from the SHC protein (pTyr317). These data and amino acid substitution analysis indicate that G1 interacts in the phosphopeptide binding site. G1 peptide requires a YXN sequence similar to that found in natural pTyr-containing ligands, and phosphorylation of the tyrosine increases G1 inhibitory activity. G1 also requires an internal disulfide bond to maintain the active binding conformation. Since the G1 peptide does not contain pTyr, it defines a new type of SH2 domain binding motif that may advance the design of Grb2 antagonists.The binding characteristics of Src homology 2 (SH2) 1 domains determine their important role as regulators of intracellular signaling (1, 2). Signal flow requires a phosphotyrosyl (pTyr) residue in the target protein for binding by the SH2 domain (1, 3, 4). Interaction of SH2 domains with specific pTyr-containing proteins activates distinct signaling pathways. SH2 domains modulate the activities of c-src (5), alter the substrate specificity of c-abl proto-oncoproteins (6, 7), and transduce signals initiated at growth factor receptors (8) and cellular attachment systems (9). SH2 domains have been suggested as promising sites for therapeutic intervention (10). Consequently, there has been significant effort to understand the structural basis of SH2 domain binding to pTyr-containing targets (11-21).The Grb2 SH2 domain binds pTyr-containing motifs within several proteins including the adapter proteins SHC (22, 23), growth factor receptors such as members of the erbB family (23-27), morphology-determining proteins such as FAK (9), and cellular oncogenes such as 28). SH2 domain binding leads to activation of important downstream pathways by bringing the nucleotide exchange factor SOS1 to the membrane environment of p21 ras (29). Other pathways may be initiated through action of the Grb2 SH3 domain as well. These pathways are suggested by experiments showing that the SH3 domains of Grb2 can bind to other proteins including dynamin (30), Vav (31, 32), Cbl (33), and several as yet unidentified targets (34). A particularly important role for Grb2 in human cancer has been proposed for cells transformed by high levels of erbB2 (HER-2 or neu) expression (35,36). In these cells, the SH2 domain...
We have recently reported the synthesis of several cyclic disulfide bridge-containing peptide analogues of dynorphin A (Dyn A), which were conformationally constrained in the putative address segment of the opioid ligand. Several of these analogues, bridged between positions 5 and 11 of Dyn A1-11-NH2, exhibited unexpected selectivities for the kappa and mu receptors of the central over the peripheral nervous systems. In order to further investigate the conformational and topographical requirements for the residues in positions 5 and 11 of these analogues, we have synthesized a systematic series of Dyn A1-11-NH2 analogues incorporating the sulfydryl containing amino acids L- and D-Cys and L- and D-Pen in positions 5 and 11, thus producing 16 cyclic peptides. In addition, Dyn A1-11-NH2, [D-Leu5]Dyn A1-11-NH2, and [D-Lys11]Dyn A1-11-NH2 were synthesized as standards. Several of these cyclic analogues, especially c[Cys5,D-Cys11] Dyn A1-11-NH2, c[Cys5, L- or D-Pen11]Dyn A1-11-NH2, c[Pen5, L-Pen11]Dyn A1-11-NH2 and c[Pen5, L- or D-Cys11]Dyn A1-11-NH2, retained the same affinity and selectivity (vs the mu and delta receptors) as the parent compound Dyn A1-11-NH2 in the guinea pig brain (GPB). These same analogues and most others exhibited a much lower activity in the guinea pig ileum (GPI), thus leading to centrally vs peripherally selective peptides, but showed a different structure-activity relationship than found previously. In a wider scope, this series of analogues also provided new insights into which amino acids (and their configurations) may be used in positions 5 and 11 of Dyn A analogues for high potency and good selectivity at kappa opioid receptors. The results obtained in the GPB suggest that requirements for binding are not the same for the kappa, mu, or delta central receptors.
We previously have reported four possible binding conformation of dynorphin A (Dyn A) for the central kappa opioid receptors, induced by the address sequence, using a molecular mechanics energy minimization approach. The lowest energy conformation was found to exhibit an alpha-helical conformation in the cyclized address sequence. It was suggested that an alpha-helical conformation in the cyclized address sequence or a helical conformation induced by the conformational characteristics of the message sequence may be important for binding potency and kappa opioid receptor selectivity. Side chain to side chain lactam bridges between the i and i + 4 positions have been shown to stabilize alpha-helical conformation. Thus, a series of cyclic lactam analogues of dynorphin A(1-11)-NH2 have been designed, synthesized and evaluated by the guinea pig brain (GPB) binding assay and guinea pig ileum (GPI) bioassay to evaluate the conformational analysis prediction and, further, to investigate the conformational requirements for high potency and selectivity for kappa opioid receptors. Positions 2-6, 3-7, and 5-9 were chosen as the sites for incorporating cyclic conformational constraints. Cyclization between D-Asp(2) and Lys(6) in c[D-Asp(2),Lys(6)]Dyn A(1-11)-NH2 led to an analogue with pronounced potency and selectivity enhancement for the mu opioid receptor, whereas cyclization between D-Asp(3) and Lys(7) in c[D-Asp(3),Lys(7)]Dyn A(1-11)-NH2 led to a potent ligand (IC(50) 4.9 nM) with kappa receptor selectivity. The other analogues in the series proved to be less selective. The biological results led to the suggestion that the binding conformation for the kappa receptor may have structural requirements that are distinct from those of mu and delta receptors. Interestingly, analogues with a D-Asp at position 2, 3, or 9 were found to be more potent for the kappa receptor than analogues with an L-Asp at the same positions. It is suggested that the incorporation of D-Asp into position 2, 3, or 9 of Dyn A(1-11)-NH2 may have stereochemical and conformational effects on the nearby amino acids which can help discriminate the preference between kappa, mu, and delta receptors.
The heptadecapeptide dynorphin A (Dyn A(1-17); H-Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-Trp-Asp-Asn-Gln-OH) was first isolated from porcine pituitary and recognized as a potent opioid a g o n i~t .~-~ It is now well established that there are at least three types of opioid receptors, namely, p, 6 , and K .~-~ However, the physiological and pharmacological roles of these receptors still need clarification, thus requiring the design and synthesis of highly potent and selective ligands. Research in this area has expanded rapidly in the past decade, with considerable effort devoted to the development of 6 and p opioid receptorselective peptide ligands primarily based onThe potential of targeting the K opioid receptor as an effector for analgesia has yet to be explored in detail.12 Previous structure-activity studies have shown that the truncated derivative, dynorphin A(l-ll)-NHz, retains the high binding potency of dynorphin A at the K receptor. Thus we and others have primarily used Dyn A(l-ll)-NHz as a template to examine the structure-activity relationships of dynorphin.13J4 Since Tyr' and Phe4 are reported to be important for opioid agonist activity, the effects of the glycine residues in positions 2 and 3 of Dyn A on the relative orientations of the two aromatic rings may be biologically i m~0 r t a n t . l~ To assess these possible effects, we have substituted Gly3 by D-and L-alanine residues to form the linear peptides [D-Ala3]Dyn A(1-11)-NHz and [Ala31Dyn A(l-ll)-NHz. We report here that both analogues are very potent for K receptors and very selective for K vs p and K vs 6 receptors. These results suggest that substitution of lipophilic residues and/or certain D-amino acids at position 3 of Dyn A(1-11)-NHz may lead to novel Dyn A analogues which exhibit enhanced selectivities for K receptors, while retaining strong affinities.Peptide Synthesis and Purification. Dynorphin A analogues were synthesized by solid phase methods that were reported previously for the synthesis of other Dyn A analogues.14J5 Side chain-protected Na-Boc amino acids were purchased from Bachem (Torrance, CA), whereas the other amino acids were synthesized by standard methods in our laboratory. The synthesized analogues were purified by RP-HPLC (linear gradient of 10-90% acetonitrile in 0.1% TFA in water over 40 min) and characterized by FAB-MS and amino acid analysis. The purity of the synthetic peptides was assessed by TLC (single spot in four different solvent
One of the critical intracellular signal transduction pathways involves the binding of the Grb2 SH2 domain to the phosphotyrosine (pTyr) motifs on growth factor receptors, such as epidermal growth factor receptor (EGFR) and erbB2, leading to downstream activation of the oncogenic Ras signaling pathway. Therefore, the Grb2 SH2 domain has been chosen as our target for the development of potential anticancer agents. As a continuation of our earlier work, herein we report the design and synthesis of new peptide analogs, and their inhibitory effect on the Grb2 SH2 domain using surface plasmon resonance (SPR) technology. These novel agents do not contain phosphotyrosine or phosphotyrosine mimics. Binding interactions between these peptides and the Grb2 SH2 domain were measured and analyzed using a BIAcore X instrument, which provides detailed information on the real-time detection of the binding interaction. The results of this study should provide important information for the further development of peptides or peptidomimetics with high affinity for the Grb2 SH2 domain.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.